Health Care & Life Sciences » Biotechnology | Arno Therapeutics Inc.

Arno Therapeutics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2011
2012
2013
2014
2015
Cash & Short Term Investments
6,678.30
10,943.40
26,774.20
7,948.40
67.00
Other Current Assets
296.90
203.50
86.30
258.00
260.70
Total Current Assets
6,975.30
11,147.00
26,860.50
8,206.50
327.70
Net Property, Plant & Equipment
38.70
24.80
11.70
30.70
23.10
Total Investments and Advances
-
-
-
10.50
-
Other Assets
10.50
1,720.00
10.50
-
10.50
Total Assets
7,024.40
12,891.80
26,882.60
8,247.70
361.20
ST Debt & Current Portion LT Debt
-
-
-
3.30
2,093.80
Accounts Payable
683.20
1,553.20
2,942.00
-
-
Other Current Liabilities
1,280.10
1,693.10
959.10
2,153.80
2,136.80
Total Current Liabilities
1,963.30
3,246.30
3,901.10
2,157.10
4,230.60
Long-Term Debt
-
491.00
-
7.90
4.10
Other Liabilities
3,705.50
21,420.30
35,864.90
6,671.50
4,750.70
Total Liabilities
5,668.80
25,157.60
39,766.00
8,836.60
8,985.30
Common Equity (Total)
1,355.60
12,265.80
12,883.30
588.90
8,624.10
Total Shareholders' Equity
1,355.60
12,265.80
12,883.30
588.90
8,624.10
Total Equity
1,355.60
12,265.80
12,883.30
588.90
8,624.10
Liabilities & Shareholders' Equity
7,024.40
12,891.80
26,882.60
8,247.70
361.20

About Arno Therapeutics

View Profile
Address
200 Route 31 North
Flemington New Jersey 08822
United States
Employees -
Website http://www.arnothera.com
Updated 07/08/2019
Arno Therapeutics, Inc. operates as a biopharmaceutical company, which focuses on the clinical development of targeted cancer therapies and novel drug candidates for unmet medical needs. It develops pre-clinical and clinical-stage product under the following brands: Onapristone, AR-42, and AR-12. The company was founded by Peter Morgan Kash, David M.